On opposite sides of the globe, Richard Scolyer and Georgina Long faced a disheartening moment as they examined a seemingly harmless brain scan. United by their friendship and expertise as leading skin cancer doctors, their concern grew as they detected an ominous anomaly in the top right corner of Prof Scolyer’s brain – a cloudy section that hinted at a formidable tumor.
While not radiology experts, their instincts told them it was more than meets the eye. Consulting neurosurgeons confirmed their fears – it was a particularly aggressive subtype of glioblastoma, a cancer with a grim prognosis, where most patients survive less than a year.
Undeterred by the devastating diagnosis, Prof Scolyer and Prof Long, both renowned Australian researchers, embarked on an improbable journey: to defy the odds and find a cure for this formidable adversary, just as they had previously achieved with melanoma.
“I couldn’t accept certain death without trying something,” asserts Prof Scolyer. “An incurable cancer? Well, to hell with that!”
Three decades earlier, when these two doctors first crossed paths, advanced melanoma was considered a death sentence. However, rather than shying away, they were drawn to the challenge. Australia, with its highest global rate of skin cancer, presented an opportunity where others saw insurmountable difficulty.
“In the past, the most challenging patients were those with advanced melanoma. It was heartbreaking,” shares Prof Long. “I wanted to make a difference.”
Their impact on the field has been profound, transforming the outlook for melanoma patients worldwide. The Melanoma Institute, which they now lead, stands as a testament to their pioneering work, shaping the landscape of melanoma diagnosis and treatment globally.
Decade of Triumphs: Pioneering Immunotherapy Transforming Cancer Treatment
In the past ten years, the research team led by Professors Richard Scolyer and Georgina Long has revolutionized cancer treatment, particularly in advanced melanoma cases, through groundbreaking immunotherapy. This innovative approach utilizes the body’s immune system to combat cancer cells, leading to a remarkable improvement in outcomes for patients globally. The once grim scenario of less than 10% survival has now shifted, with half of advanced melanoma patients essentially cured.
Termed a “penicillin moment” by Prof Long, this breakthrough isn’t confined to melanoma alone; it’s extending its life-saving impact to various other cancers. The profound influence of their work has elevated them to the status of national treasures in Australia. Their contributions touch the lives of countless individuals, prompting their joint recognition as Australians of the Year.
As they spearheaded transformative changes in the medical landscape, Professors Scolyer and Long weren’t just shaping the future of cancer treatment; they were also leaving an indelible mark on each other. United by a shared frustration over unsolved cases, the euphoria of groundbreaking discoveries, a passion for exercise, and the ambitious goal of achieving zero melanoma deaths in Australia, their unique partnership exemplifies a ‘get things done’ approach, despite their differences.
A Medical Oncologist’s Devotion: Prof Scolyer’s Battle with Glioblastoma
With eyes gleaming, the medical oncologist passionately enumerates the admirable qualities that define Prof Scolyer – bravery, honesty, optimism, and an unyielding drive – making him the ideal colleague and friend.
Receiving a distressing call from Poland last June, where Prof Scolyer was vacationing when a seizure led to his diagnosis, the oncologist spent a tearful night grappling with the possibility of losing her friend within a year.
“Grieving and thinking my friend is going to be gone in 12 months,” she recalls.
Yet, with the dawn came a resilient resolve. The mourning transitioned into strategic action, as she delved into textbooks, explored clinical trials, and reached out to colleagues worldwide.
Glioblastomas, notorious for their aggressiveness and located in the brain’s connective tissue, have seen little progress in treatment protocols over the past two decades. The standard approach involves immediate excision followed by radiotherapy and chemotherapy. However, survival rates remain disheartening, with only 5% of patients surviving beyond five years.
In the face of desperation, Prof Long conceived a bold and innovative plan to treat Prof Scolyer, drawing inspiration from successful strategies in melanoma treatment that had never been tested in the realm of brain cancer.
Navigating Risks and Rewards: Pioneering Immunotherapy in Glioblastoma Treatment
In the realm of melanoma, Prof Long and her team uncovered a crucial principle: the efficacy of immunotherapy is heightened when a combination of drugs is administered before any tumor-removing surgery. Drawing a vivid analogy, she likens it to training a sniffer dog – exposing it to the scent of contraband (here, cancer cells) to enhance its ability to track them down later.
For Prof Scolyer, opting for this treatment seemed like a “no brainer,” despite the monumental risks involved. Skepticism loomed among some oncologists, questioning whether the drugs could effectively reach his brain and if his immune system would respond. The fear was that the experimental approach might accelerate his decline.
The urgency of many brain cancers added to the dilemma; a mere two-week delay to surgery could render it too late for intervention. Additionally, the toxicity of immunotherapy drugs, particularly in combination, raised concerns about potential poisoning. Any adverse reactions leading to brain swelling could have dire consequences.
Amidst these risks, some colleagues privately expressed apprehension, suggesting that emotional ties might be clouding Prof Long’s judgment. However, she stood firm in her conviction, asserting, “[But] he needs us… We have all this depth of knowledge; it’s our duty.”
The story unfolds against the backdrop of the delicate balance between the potential rewards of groundbreaking treatment and the formidable risks that accompany venturing into uncharted medical territories.
Trailblazing Treatment: Prof Scolyer’s Unprecedented Immunotherapy Journey
Guided by Prof Long and a dedicated team of experts, Prof Scolyer embarked on an unprecedented medical journey, becoming the inaugural brain cancer patient to undergo a combination of pre-surgery immunotherapy.
In a groundbreaking move, he also holds the distinction of being the first recipient of a personalized vaccine tailored to his tumor markers. This innovative approach aims to enhance the cancer-detecting capabilities of the administered drugs, marking a significant advancement in the quest for effective brain cancer treatment.
‘A Glimmer of Hope’: Remarkable Progress in Brain Cancer Treatment
In the aftermath of the life-altering scan, Prof Scolyer and Prof Long found themselves scrutinizing another crucial test result – an analysis of the tumor extracted from Prof Scolyer’s skull. The revelation left them astonished and hopeful.
“In a millisecond, it was bloody obvious that it is doing something,” Prof Scolyer recalls.
Traces of the drugs within the tumor provided tangible proof that the medication had reached his brain. More significantly, an influx of activated immune cells was observed, sparking optimism that they were actively attacking his cancer cells.
Glioblastoma cancers typically resurface around six months post-surgery. However, after eight months of ongoing immunotherapy, Prof Scolyer is defying expectations, displaying no signs of active cancer. A recent clean scan suggests a normalization of his brain.
The promising results have generated considerable excitement, offering not only hope for prolonging Prof Scolyer’s life but also fostering optimism about a potential breakthrough that could benefit the 300,000 individuals diagnosed with brain cancer globally each year.
This accelerated progress, achieved in a matter of months, has captured the attention of pharmaceutical companies and spurred discussions about the possibility of swift clinical trials.
Differing Opinions on Progress: Assessing Prof Scolyer’s Treatment
While the recent progress in Prof Scolyer’s treatment has stirred excitement, Dr. Roger Stupp, the namesake of the current protocol for glioblastoma treatment, urges caution. He describes Prof Scolyer’s prognosis as “grim” and deems it too early to determine the treatment’s effectiveness.
Preferring the term “encouraging” over “promising,” Dr. Stupp, speaking from Chicago, emphasizes that it represents a step forward but falls short of a revolutionary breakthrough. He cautiously awaits evidence of Prof Scolyer’s sustained progress, ideally reaching 12 to 18 months without recurrence.
Dr. Stupp expresses unwavering confidence in the potential of immunotherapy to reshape brain cancer treatment, stressing the need to explore insights from various tumor types.
Prof Scolyer and Prof Long, while hopeful, resist getting swept up in the buzz. Acknowledging the minuscule odds of a cure, they cautiously navigate the best-case scenario while celebrating Prof Scolyer’s 57th birthday and another Christmas with his family, cherishing each moment beyond the initially grim prognosis.
Navigating Emotional Terrain: Prof Scolyer’s Journey Beyond Milestones
Amidst the gratitude for each additional milestone and every clear scan, there lingers the palpable fear that it might be Prof Scolyer’s last. The emotional weight of treating a friend is evident, as Prof Long shares the challenges they face, including discussions about death and funerals. Despite Prof Scolyer’s resilience, the reality of his situation is ever-present.
In his office, surrounded by images of his children, tasks outlined on a whiteboard, and shelves adorned with framed accolades, Prof Scolyer’s vulnerability surfaces. While outwardly positive, he tearfully admits to feeling scared and soul-crushingly sad. Expressing love for his family, appreciation for his wife, and a fondness for his work, he grimaces as he articulates his deep emotions.
“I’m pissed off. I’m devastated… I don’t want to die,” he confesses.
Amidst the turmoil, the potential solace lies in the notion that the research spawned from his diagnosis could infuse meaning and purpose into his journey. Prof Scolyer finds comfort in the impact of the data generated, acknowledging its transformative influence on the field. Regardless of the uncertainties ahead, he expresses pride in contributing to a changing landscape and shaping the future of cancer research.
A Personal Odyssey: Prof Scolyer’s Emotional Landscape
Brimming with gratitude for each milestone and clear scan, Prof Scolyer grapples with the ever-present fear that the next may be his last. In the emotionally charged realm of treating a friend, discussions about death and funerals become inevitable, revealing the challenges faced by Prof Long and the entire team.
In the sanctum of his office, adorned with pictures of his children, tasks scrawled on a whiteboard, and shelves filled with framed accolades, Prof Scolyer’s emotional vulnerability surfaces. Despite projecting outward positivity, tears well up as he candidly acknowledges his fear and profound sadness. Expressing love for his family, deep affection for his wife, and a genuine passion for his work, he grimaces while revealing his inner turmoil.
“I’m pissed off. I’m devastated… I don’t want to die,” he admits.
Yet, amidst this emotional storm, a glimmer of solace emerges – the belief that the research spawned from his diagnosis could inject meaning and purpose into his journey. Prof Scolyer finds comfort in the transformative impact of the data generated, taking pride in contributing to a shifting landscape and shaping the future of cancer research.